BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24343741)

  • 1. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
    Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
    Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
    Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
    Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
    Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
    Lee AF; Gown AM; Churg A
    Am J Surg Pathol; 2013 Mar; 37(3):421-6. PubMed ID: 23108021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid].
    Lyu M; Cha N; Zou YF; Leng JH; Xu L; Sun Y; Hao YY
    Zhonghua Bing Li Xue Za Zhi; 2018 Mar; 47(3):180-185. PubMed ID: 29534357
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
    Kushitani K; Amatya VJ; Mawas AS; Miyata Y; Okada M; Takeshima Y
    Pathobiology; 2016; 83(1):33-40. PubMed ID: 26735863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
    Attanoos RL; Griffin A; Gibbs AR
    Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
    Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
    Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesothelioma.
    Okazaki Y; Nagai H; Chew SH; Li J; Funahashi S; Tsujimura T; Toyokuni S
    Cancer Sci; 2013 Aug; 104(8):989-95. PubMed ID: 23621518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelial proliferations: useful marker is not the same as a diagnostic one.
    Husain AN
    Am J Clin Pathol; 2014 Feb; 141(2):152-3. PubMed ID: 24436261
    [No Abstract]   [Full Text] [Related]  

  • 19. Measurement of telomere length in cells from pleural effusion: Asbestos exposure causes telomere shortening in pleural mesothelial cells.
    Aida S; Aida J; Naoi M; Kato M; Tsuura Y; Natsume I; Takubo K
    Pathol Int; 2018 Sep; 68(9):503-508. PubMed ID: 30098092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations.
    Salisbury T; Churg A
    Virchows Arch; 2021 Nov; 479(5):1047-1050. PubMed ID: 33721119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.